Skip to main content

Advertisement

SpringerLink
Log in

HIV therapy, metabolic syndrome, and cardiovascular risk

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

People with HIV infection have metabolic abnormalities that resemble metabolic syndrome (hypertriglyceridemia, low high-density lipoprotein cholesterol, and insulin resistance), which is known to predict increased risk of cardiovascular disease (CVD). However, there is not one underlying cause for these abnormalities and they are not linked to each other. Rather, individual abnormalities can be affected by the host response to HIV itself, specific HIV drugs, classes of HIV drugs, HIV-associated lipoatrophy, or restoration to health. Furthermore, one component of metabolic syndrome, increased waist circumference, occurs less frequently in HIV infection. Thus, HIV infection supports the concept that metabolic syndrome does not represent a syndrome based on a common underlying pathophysiology. As might be predicted from these findings, the prevalence of CVD is higher in people with HIV infection. It remains to be determined whether CVD rates in HIV infection are higher than might be predicted from traditional risk factors, including smoking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.

    Article  PubMed  Google Scholar 

  2. Lee GA, Rao MN, Grunfeld C: The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005, 2:39–50.

    Article  PubMed  Google Scholar 

  3. Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493–2505.

    Article  PubMed  CAS  Google Scholar 

  4. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.

    Google Scholar 

  6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.

  7. Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438.

    Article  PubMed  Google Scholar 

  8. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetes Med 2006, 23:469–480.

    Article  CAS  Google Scholar 

  9. Balkau B, Charles MA, Drivsholm T, et al.: Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002, 28:364–376.

    PubMed  Google Scholar 

  10. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304.

    Article  PubMed  Google Scholar 

  11. Bergersen BM, Schumacher A, Sandvik L, et al.: Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2006, 38:682–689.

    Article  PubMed  Google Scholar 

  12. Bernal E, Masia M, Padilla S, et al.: Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort [Spanish]. Med Clin (Barc) 2007, 128:172–175.

    Article  Google Scholar 

  13. Bonfanti P, Giannattasio C, Ricci E, et al.: HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45:426–431.

    Article  PubMed  Google Scholar 

  14. Bonfanti P, Ricci E, de Socio G, et al.: Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128–131.

    Article  PubMed  Google Scholar 

  15. Bruno R, Gazzaruso C, Sacchi P, et al.: High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr 2002, 31:363–365.

    PubMed  Google Scholar 

  16. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, et al.: Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55:940–945.

    Article  PubMed  CAS  Google Scholar 

  17. Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377–1382.

    Article  PubMed  CAS  Google Scholar 

  18. Gazzaruso C, Sacchi P, Garzaniti A, et al.: Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002, 25:1253–1254.

    Article  PubMed  Google Scholar 

  19. Jacobson DL, Tang AM, Spiegelman D, et al.: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43:458–466.

    Article  PubMed  Google Scholar 

  20. Jerico C, Knobel H, Montero M, et al.: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132–137.

    Article  PubMed  Google Scholar 

  21. Mondy K, Overton ET, Grubb J, et al.: Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44:726–734.

    Article  PubMed  Google Scholar 

  22. Samaras K, Wand H, Law M, et al.: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113–119.

    Article  PubMed  CAS  Google Scholar 

  23. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.

    Article  PubMed  CAS  Google Scholar 

  24. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045–1052.

    Article  PubMed  CAS  Google Scholar 

  25. El-Sadr WM, Mullin CM, Carr A, et al.: Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005, 6:114–121.

    Article  PubMed  CAS  Google Scholar 

  26. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641–649.

    Article  PubMed  CAS  Google Scholar 

  27. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11–F18.

    Article  PubMed  CAS  Google Scholar 

  28. Noor MA, Parker RA, O’Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137–2144.

    Article  PubMed  CAS  Google Scholar 

  29. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal patients. AIDS 2000, 14:51–57.

    Article  PubMed  CAS  Google Scholar 

  30. van der Valk M, Kastelein JJ, Murphy RL, et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001, 15:2407–2414.

    Article  PubMed  Google Scholar 

  31. Riddle TM, Schildmeyer NM, Phan C, et al.: The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002, 43:1458–1463.

    Article  PubMed  CAS  Google Scholar 

  32. van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.

    Article  PubMed  Google Scholar 

  33. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  34. Fontas E, van Leth F, Sabin CA, et al.: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004, 189:1056–1074.

    Article  PubMed  CAS  Google Scholar 

  35. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1–F8.

    Article  PubMed  Google Scholar 

  36. Lee GA, Rao MN, Mulligan K, et al.: The Effects of ritonavir and amprenavir on insulin-mediated glucose disposal in healthy volunteers: two randomized, placebo-controlled, cross-over trials. AIDS 2007, In press.

  37. Lee GA, Lo JC, Aweeka F, et al.: Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006, 43:658–660.

    Article  PubMed  CAS  Google Scholar 

  38. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by hiv protease inhibitor therapy. J Biol Chem 2000, 275:20251–20254.

    Article  PubMed  CAS  Google Scholar 

  39. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  40. Schwarz JM, Lee GA, Park S, et al.: Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004, 18:1852–1854.

    Article  PubMed  Google Scholar 

  41. Noor MA, Flint OP, Maa JF, Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006, 20:1813–1821.

    Article  PubMed  CAS  Google Scholar 

  42. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121–131.

  43. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562–571.

  44. Grunfeld C, Rimland D, Gibert CL, et al.: Association of upper trunk and visceral adipose tissue. J Acquir Immune Defic Syndr 2007 [Epub ahead of print].

  45. Bergersen BM, Sandvik L, Dunlop O, et al.: Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003, 22:731–736.

    Article  PubMed  CAS  Google Scholar 

  46. Palacios R, Santos J, Garcia A, et al.: Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006, 7:10–15.

    Article  PubMed  CAS  Google Scholar 

  47. Seaberg EC, Munoz A, Lu M, et al.: Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005, 19:953–960.

    Article  PubMed  Google Scholar 

  48. Thiebaut R, El-Sadr WM, Friis-Moller N, et al.: Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005, 10:811–823.

    PubMed  Google Scholar 

  49. Feingold K, Krauss R, Pang M, et al.: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993, 76:1423–1427.

    Article  PubMed  CAS  Google Scholar 

  50. Khovidhunkit W, Kim MS, Memon RA, et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169–1196.

    Article  PubMed  CAS  Google Scholar 

  51. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immuno-deficiency virus infection. N Engl J Med 2003, 348:702–710.

    Article  PubMed  CAS  Google Scholar 

  52. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471–477.

    PubMed  CAS  Google Scholar 

  53. Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993–2003.

    Article  PubMed  Google Scholar 

  54. Friis-Moller N, Reiss P, Sabin CA, et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723–1735.

    Article  PubMed  Google Scholar 

  55. Coplan PM, Nikas A, Japour A, et al.: Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003, 19:449–455.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Veterans Affairs Medical Center, Metabolism Section (Box 111F), 4150 Clement Street, San Francisco, CA, 94121, USA

    Carl Grunfeld

Authors
  1. Vivian Pao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grace A. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carl Grunfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl Grunfeld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pao, V., Lee, G.A. & Grunfeld, C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 10, 61–70 (2008). https://doi.org/10.1007/s11883-008-0010-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0010-6

Keywords

Search

Navigation